Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
about
The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.Sarilumab: First Global Approval.The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.A review of sarilumab for the treatment of rheumatoid arthritis.Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
P2860
Q38685086-3A7AD085-C07A-4E38-AEFF-DE9E37140B6FQ38745066-2D9CDF10-A9E9-4AF7-B291-23AA7922D7BBQ39015080-BF2587CF-4D39-4BFE-AA7B-15D454E15FE0Q39177162-15808975-8EA1-4171-A73C-519F48F05725Q39215645-C9C7DA58-ABA7-4175-A29A-B06A45D06DF0Q50086851-275AA99C-16AF-4F30-90DE-0A75F4985980Q50334739-79C14146-6786-47A7-A655-77EE1EB77815Q52647587-440FAFCD-63C4-4C65-A86D-1070D42E9D7B
P2860
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY
@en
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY.
@nl
type
label
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY
@en
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY.
@nl
prefLabel
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY
@en
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY.
@nl
P2093
P2860
P1476
Sarilumab plus methotrexate su ...... a biomarker study of MOBILITY
@en
P2093
Anita Boyapati
Janet van Adelsberg
Jennifer D Hamilton
Jérôme Msihid
Neil M H Graham
Stefano Fiore
P2860
P2888
P356
10.1186/S13075-016-1132-9
P577
2016-10-06T00:00:00Z
P6179
1025918165